NEVRO CORP (NVRO) Stock Fundamental Analysis

NYSE:NVRO • US64157F1030

5.84 USD
0 (0%)
At close: Apr 2, 2025
5.8401 USD
0 (0%)
After Hours: 4/2/2025, 8:04:00 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

2

NVRO gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 186 industry peers in the Health Care Equipment & Supplies industry. NVRO has a bad profitability rating. Also its financial health evaluation is rather negative. NVRO is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

2

1. Profitability

1.1 Basic Checks

  • In the past year NVRO has reported negative net income.
  • NVRO had a negative operating cash flow in the past year.
  • In the past 5 years NVRO reported 4 times negative net income.
  • The reported operating cash flow has been mixed in the past 5 years: NVRO reported negative operating cash flow in multiple years.
NVRO Yearly Net Income VS EBIT VS OCF VS FCFNVRO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -50M -100M

1.2 Ratios

  • The Return On Assets of NVRO (-20.48%) is comparable to the rest of the industry.
  • The Return On Equity of NVRO (-49.11%) is comparable to the rest of the industry.
Industry RankSector Rank
ROA -20.48%
ROE -49.11%
ROIC N/A
ROA(3y)-11.5%
ROA(5y)-13.58%
ROE(3y)-26.55%
ROE(5y)-28.86%
ROIC(3y)N/A
ROIC(5y)N/A
NVRO Yearly ROA, ROE, ROICNVRO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -10 -20 -30 -40

1.3 Margins

  • NVRO's Gross Margin of 65.98% is fine compared to the rest of the industry. NVRO outperforms 68.06% of its industry peers.
  • In the last couple of years the Gross Margin of NVRO has remained more or less at the same level.
  • The Profit Margin and Operating Margin are not available for NVRO so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 65.98%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.17%
GM growth 5Y-0.71%
NVRO Yearly Profit, Operating, Gross MarginsNVRO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 40 60

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

3

2. Health

2.1 Basic Checks

  • NVRO does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • NVRO has more shares outstanding than it did 1 year ago.
  • NVRO has more shares outstanding than it did 5 years ago.
  • Compared to 1 year ago, NVRO has a worse debt to assets ratio.
NVRO Yearly Shares OutstandingNVRO Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M
NVRO Yearly Total Debt VS Total AssetsNVRO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

2.2 Solvency

  • NVRO has an Altman-Z score of -0.62. This is a bad value and indicates that NVRO is not financially healthy and even has some risk of bankruptcy.
  • NVRO's Altman-Z score of -0.62 is in line compared to the rest of the industry. NVRO outperforms 42.93% of its industry peers.
  • A Debt/Equity ratio of 0.98 indicates that NVRO is somewhat dependend on debt financing.
  • With a Debt to Equity ratio value of 0.98, NVRO is not doing good in the industry: 73.30% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity 0.98
Debt/FCF N/A
Altman-Z -0.62
ROIC/WACCN/A
WACC8.29%
NVRO Yearly LT Debt VS Equity VS FCFNVRO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M 200M 300M

2.3 Liquidity

  • NVRO has a Current Ratio of 4.62. This indicates that NVRO is financially healthy and has no problem in meeting its short term obligations.
  • The Current ratio of NVRO (4.62) is better than 73.82% of its industry peers.
  • NVRO has a Quick Ratio of 3.62. This indicates that NVRO is financially healthy and has no problem in meeting its short term obligations.
  • Looking at the Quick ratio, with a value of 3.62, NVRO is in the better half of the industry, outperforming 70.68% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 4.62
Quick Ratio 3.62
NVRO Yearly Current Assets VS Current LiabilitesNVRO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

3

3. Growth

3.1 Past

  • The Earnings Per Share has grown by an impressive 25.29% over the past year.
  • The Revenue has decreased by -3.92% in the past year.
  • NVRO shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 0.92% yearly.
EPS 1Y (TTM)25.29%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-60%
Revenue 1Y (TTM)-3.92%
Revenue growth 3Y1.83%
Revenue growth 5Y0.92%
Sales Q2Q%-9.15%

3.2 Future

  • The Earnings Per Share is expected to grow by 7.68% on average over the next years.
  • NVRO is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 4.43% yearly.
EPS Next Y-29.92%
EPS Next 2Y-6.37%
EPS Next 3Y-1.23%
EPS Next 5Y7.68%
Revenue Next Year0.32%
Revenue Next 2Y2.33%
Revenue Next 3Y3.23%
Revenue Next 5Y4.43%

3.3 Evolution

  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
NVRO Yearly Revenue VS EstimatesNVRO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 100M 200M 300M 400M 500M
NVRO Yearly EPS VS EstimatesNVRO Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 -1 -2 -3

More info and screens

Find the best growth stocksShow best growing peers

0

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for NVRO. In the last year negative earnings were reported.
  • Also next year NVRO is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
NVRO Price Earnings VS Forward Price EarningsNVRO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
NVRO Per share dataNVRO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 6 8 10

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-6.37%
EPS Next 3Y-1.23%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • No dividends for NVRO!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

Find the best dividend stocksShow peers with best dividend

NEVRO CORP

NYSE:NVRO (4/2/2025, 8:04:00 PM)

After market: 5.8401 0 (0%)

5.84

0 (0%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)03-04
Earnings (Next)05-05
Inst Owners99.47%
Inst Owner Change0%
Ins Owners2.02%
Ins Owner Change0%
Market Cap221.22M
Revenue(TTM)408.52M
Net Income(TTM)-113.44M
Analysts53.68
Price Target8.87 (51.88%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)49.9%
Min EPS beat(2)49.33%
Max EPS beat(2)50.46%
EPS beat(4)4
Avg EPS beat(4)42.48%
Min EPS beat(4)24.11%
Max EPS beat(4)50.46%
EPS beat(8)8
Avg EPS beat(8)30.85%
EPS beat(12)11
Avg EPS beat(12)217.02%
EPS beat(16)15
Avg EPS beat(16)164.13%
Revenue beat(2)2
Avg Revenue beat(2)1.5%
Min Revenue beat(2)0.92%
Max Revenue beat(2)2.09%
Revenue beat(4)3
Avg Revenue beat(4)0.05%
Min Revenue beat(4)-4.87%
Max Revenue beat(4)2.09%
Revenue beat(8)5
Avg Revenue beat(8)0.76%
Revenue beat(12)5
Avg Revenue beat(12)0.11%
Revenue beat(16)7
Avg Revenue beat(16)0.05%
PT rev (1m)0%
PT rev (3m)10.28%
EPS NQ rev (1m)0%
EPS NQ rev (3m)6.89%
EPS NY rev (1m)0.24%
EPS NY rev (3m)1.14%
Revenue NQ rev (1m)-1.34%
Revenue NQ rev (3m)-1.97%
Revenue NY rev (1m)-0.01%
Revenue NY rev (3m)0.21%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.54
P/FCF N/A
P/OCF N/A
P/B 0.96
P/tB 1.07
EV/EBITDA N/A
EPS(TTM)-1.92
EYN/A
EPS(NY)-2.49
Fwd EYN/A
FCF(TTM)-0.77
FCFYN/A
OCF(TTM)-0.51
OCFYN/A
SpS10.78
BVpS6.1
TBVpS5.45
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -20.48%
ROE -49.11%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 65.98%
FCFM N/A
ROA(3y)-11.5%
ROA(5y)-13.58%
ROE(3y)-26.55%
ROE(5y)-28.86%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.17%
GM growth 5Y-0.71%
F-Score2
Asset Turnover0.74
Health
Industry RankSector Rank
Debt/Equity 0.98
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 89.79%
Cap/Sales 2.4%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.62
Quick Ratio 3.62
Altman-Z -0.62
F-Score2
WACC8.29%
ROIC/WACCN/A
Cap/Depr(3y)111.23%
Cap/Depr(5y)142.49%
Cap/Sales(3y)2.09%
Cap/Sales(5y)2.23%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)25.29%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-60%
EPS Next Y-29.92%
EPS Next 2Y-6.37%
EPS Next 3Y-1.23%
EPS Next 5Y7.68%
Revenue 1Y (TTM)-3.92%
Revenue growth 3Y1.83%
Revenue growth 5Y0.92%
Sales Q2Q%-9.15%
Revenue Next Year0.32%
Revenue Next 2Y2.33%
Revenue Next 3Y3.23%
Revenue Next 5Y4.43%
EBIT growth 1Y11.35%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year86.02%
EBIT Next 3Y28.25%
EBIT Next 5Y19.53%
FCF growth 1Y56.65%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y66.96%
OCF growth 3YN/A
OCF growth 5YN/A

NEVRO CORP / NVRO FAQ

What is the fundamental rating for NVRO stock?

ChartMill assigns a fundamental rating of 2 / 10 to NVRO.


What is the valuation status of NEVRO CORP (NVRO) stock?

ChartMill assigns a valuation rating of 0 / 10 to NEVRO CORP (NVRO). This can be considered as Overvalued.


How profitable is NEVRO CORP (NVRO) stock?

NEVRO CORP (NVRO) has a profitability rating of 2 / 10.


Can you provide the financial health for NVRO stock?

The financial health rating of NEVRO CORP (NVRO) is 3 / 10.


What is the expected EPS growth for NEVRO CORP (NVRO) stock?

The Earnings per Share (EPS) of NEVRO CORP (NVRO) is expected to decline by -29.92% in the next year.